MUC1 Inhibition Reverses the Poor Immunogenicity of Leukemia Stem Cells Rendering Them Susceptible to Immunotherapy

Dina Stroopinsky(Beth Israel Deaconess Medical Center), David Avigan(Beth Israel Deaconess Medical Center), Robin Joyce(Beth Israel Deaconess Medical Center), Ilene Galinsky(Dana-Farber Cancer Institute), Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), Brett Glotzbecker(Dana-Farber Cancer Institute), Katarina Luptakova(Tesaro (United States)), Donald Küfe(Dana-Farber Cancer Institute), Richard M. Stone(Dana-Farber Cancer Institute), Baldev Vasir(Beth Israel Deaconess Medical Center), Dimitrios Tzachanis(Dana-Farber Cancer Institute), Heidi Mills(Beth Israel Deaconess Medical Center), Yoram Reiter(Technion – Israel Institute of Technology), James D. Levine(Beth Israel Deaconess Medical Center), Jon Arnason(Beth Israel Deaconess Medical Center)
Blood
November 18, 2011
10.1182/blood.v118.21.1883.1883
Cited by 1

Related Papers

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
|The Lancet|2021|1.7k
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
|Blood|2017|1.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k